ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Tankyevych, Olena; Trousset, Flora; Latappy, Claire; Berraho, Moran; Dutilh, Julien; Tasu, Jean Pierre; Lamour, Corinne; Cheze Le Rest, Catherine
Cancers2022-12DOI: 10.3390/cancers14235931
10被引8阅读
引用收藏
分享

摘要

Simple Summary In locally advanced or metastatic non-small cell lung cancer (NSCLC), immunotherapy has become a standard as it can improve overall survival and progression-free survival. However, a durable clinical benefit (DCB) is only achieved in 20-50% of patients. Early identification of patients likely to benefit from this treatment is not only challenging but also crucial to avoid immune-related toxicities in patients unlikely to achieve DCB. The aim of our retrospective study was to assess the value of baseline and serial FDG-PET/CT radiomics for the prediction of response and survival in NSCLC patients undergoing immunotherapy. In a group of 83 patients, multimodality radiomics and delta-radiomics models provided added predictive value compared to conventional clinical parameters. Multimodality radiomics-based models developed using appropriate machine learning processes were able to predict progression, DCB, Overall Survival and Progression Free Survival with high confidence. Purpose: We aimed to assess the ability of radiomics features extracted from baseline (PET/CT0) and follow-up PET/CT scans, as well as their evolution (delta-radiomics), to predict clinical outcome (durable clinical benefit (DCB), progression, response to therapy, OS and PFS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy. Methods: 83 NSCLC patients treated with immunotherapy who underwent a baseline PET/CT were retrospectively included. Response was assessed at 6-8 weeks (PET/CT1) using PERCIST criteria and at 3 months with iPERCIST (PET/CT2) or RECIST 1.1 criteria using CT. The predictive performance of clinical parameters (CP), standard PET metrics (SUV, Metabolic Tumor volume, Total Lesion Glycolysis), delta-radiomics and PET and CT radiomics features extracted at baseline and during follow-up were studied. Seven multivariate models with different combinations of CP and radiomics were trained on a subset of patients (75%) using least absolute shrinkage, selection operator (LASSO) and random forest classification with 10-fold cross-validation to predict outcome. Model validation was performed on the remaining patients (25%). Overall and progression-free survival was also performed by Kaplan-Meier survival analysis. Results: Numerous radiomics and delta-radiomics parameters had a high individual predictive value of patient outcome with areas under receiver operating characteristics curves (AUCs) >0.80. Their performance was superior to that of CP and standard PET metrics. Several multivariate models were also promising, especially for the prediction of progression (AUCs of 1 and 0.96 for the training and testing subsets with the PET-CT model (PET/CT0)) or DCB (AUCs of 0.85 and 0.83 with the PET-CT-CP model (PET/CT0)). Conclusions: Delta-radiomics and radiomics features extracted from baseline and follow-up PET/CT images could predict outcome in NSCLC patients treated with immunotherapy and identify patients who would benefit from this new standard. These data reinforce the rationale for the use of advanced image analysis of PET/CT scans to further improve personalized treatment management in advanced NSCLC.

学科与关键词

关键词
PETCTradiomicsNSCLCimmunotherapyresponse to therapydurable clinical benefitsurvival
相关
加载中…
  • Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
    Wu, Shaowei; Zhan, Weijie; Liu, Lan; Xie, Daipeng; Yao, Lintong; Yao, Henian; Liao, Guoqing; Huang, Luyu; Zhou, Yubo; You, Peimeng; Huang, Zekai; Li, Qiaxuan; Xu, Bin; Wang, Siyun; Wang, Guangyi; Zhang, Dong-Kun; Qiao, Guibin; Chan, Lawrence Wing-Chi; Lanuti, Michael; Zhou, Haiyu*Journal for ImmunoTherapy of Cancer, 2023, 11(10): e007369.
  • Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
    Han, Xiaoyu; Wang, Mingliang; Zheng, Yuting; Wang, Na; Wu, Ying; Ding, Chengyu; Jia, Xi; Yang, Ran; Geng, Mingfei; Chen, Zhen; Zhang, Songlin; Zhang, Kailu; Li, Yumin; Liu, Jia; Gu, Jin; Liao, Yongde*; Fan, Jun*; Shi, Heshui*European Radiology, 2023.
  • PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature
    Evangelista, Laura*; Fiz, Francesco; Laudicella, Riccardo; Bianconi, Francesco; Castello, Angelo; Guglielmo, Priscilla; Liberini, Virginia; Manco, Luigi; Frantellizzi, Viviana; Giordano, Alessia; Urso, Luca; Panareo, Stefano; Palumbo, Barbara; Filippi, LucaCancers, 2023, 15(12): 3258.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancers
发表日期
2022-12
卷期
第 14 卷, 第 23 期
页码
5931
DOI
10.3390/cancers14235931
期刊等级
2区
成果收录
SCIE

作者

  • T

    Tankyevych, Olena (第一作者)

  • T

    Trousset, Flora

查看全部 8 位作者收起作者
  • L

    Latappy, Claire

  • B

    Berraho, Moran

  • D

    Dutilh, Julien

  • T

    Tasu, Jean Pierre

  • L

    Lamour, Corinne

  • C

    Cheze Le Rest, Catherine

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417